Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. covers the 2024 Annual Meeting of Stockholders held on May 14, 2024. The filing details the voting results for three proposals presented to shareholders, as previously described in the Definitive Proxy Statement filed on April 3, 2024.
Key Financial Metrics
This filing is a corporate governance report regarding shareholder voting results. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial performance details.
Material Changes and Voting Results
The filing reports the outcomes of three specific shareholder proposals:
- Proposal 1: Election of Director
- Alan Edrick was elected as a Class III Director for a three-year term ending in 2027.
- Votes For: 19,722,574
- Votes Withheld: 10,861,497
- Broker Non-Votes: 4,292,458
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes For: 34,794,995
- Votes Against: 73,003
- Votes Abstained: 8,531
- Broker Non-Votes: None
- Proposal 3: Executive Compensation (Say-on-Pay)
- Stockholders approved the compensation of Named Executive Officers via a non-binding advisory vote.
- Votes For: 27,472,149
- Votes Against: 903,608
- Votes Abstained: 2,208,314
- Broker Non-Votes: 4,292,458
Guidance, Outlook, and Risks
This filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It is strictly a disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the tenure of the newly elected director, Alan Edrick, which extends until the 2027 annual meeting.
- Confirm the appointment of Grant Thornton LLP as the auditor for the fiscal year ending December 31, 2024.
- Note the significant number of votes withheld (approx. 35%) on the director election and the substantial abstentions (approx. 7%) on the executive compensation vote.
- Review the Definitive Proxy Statement (filed April 3, 2024) for detailed context on the director nominee and executive compensation packages.